Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators. Malka D, et al. Among authors: dollinger m. Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19. Lancet Oncol. 2014. PMID: 24852116 Free PMC article. Clinical Trial.
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E. Kullmann F, et al. Among authors: dollinger mm. Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2. Oncology. 2011. PMID: 21894049 Clinical Trial.
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M; Working Group of Internal Oncology. Moehler M, et al. Among authors: dollinger mm. Eur J Cancer. 2014 Dec;50(18):3125-35. doi: 10.1016/j.ejca.2014.09.013. Epub 2014 Oct 15. Eur J Cancer. 2014. PMID: 25446376 Free article. Clinical Trial.
PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival.
Friedrich K, Wannhoff A, Kattner S, Brune M, Hov JR, Weiss KH, Antoni C, Dollinger M, Neumann-Haefelin C, Seufferlein T, Schemmer P, Schirmacher P, Stremmel W, Gotthardt DN. Friedrich K, et al. Among authors: dollinger m. J Gastroenterol Hepatol. 2014;29(7):1477-84. doi: 10.1111/jgh.12540. J Gastroenterol Hepatol. 2014. PMID: 25273282
319 results